-
961
-
962
-
963
-
964
Post-traumatic arthritis: overview on pathogenic mechanisms and role of inflammation
Published 2016-09-01Get full text
Article -
965
COVID-19, A New Possible Mimicker of Interstitial Lung Disease Related to Primary Sjögren’s Syndrome
Published 2023-01-01Get full text
Article -
966
-
967
How to Distinguish Patients with pSS among Individuals with Dryness without Invasive Diagnostic Studies
Published 2018-01-01Get full text
Article -
968
Effects of Severe Hypoxia on Bone Marrow Mesenchymal Stem Cells Differentiation Potential
Published 2013-01-01Get full text
Article -
969
-
970
The research progress of biologics in elderly-onset rheumatoid arthritis (EORA)
Published 2025-01-01Get full text
Article -
971
Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction
Published 2021-01-01Get full text
Article -
972
The Potential Importance of MicroRNAs as Novel Indicators How to Manage Patients with Juvenile Idiopathic Arthritis More Effectively
Published 2021-01-01“…It is complemented with other miRNAs possibly relevant for JIA (miR-145, miR-23b, miR-27a, and miR-204) and discussion on challenges for using miRNAs in pediatric rheumatology (particularly, issues regarding specificity of biomarkers and measurements involving synovial fluid).…”
Get full text
Article -
973
Leprosy with Atypical Skin Lesions Masquerading as Relapsing Polychondritis
Published 2016-01-01Get full text
Article -
974
A Case of “Refractory” Neuropsychiatric Lupus Responsive to Anticoagulation
Published 2017-01-01Get full text
Article -
975
-
976
-
977
Mutation in the COL2A1 gene is associated with acetabular dysplasia
Published 2025-01-01Get full text
Article -
978
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
Published 2024-10-01“…Efficacy assessments up to week 156 include American College of Rheumatology 20% response (ACR20), Disease Activity Score 28 using C-reactive protein of <2.6, Clinical Disease Activity Index of ≤2.8, Simplified Disease Activity Index of ≤3.3 and Boolean remission (1.0 and 2.0) with non-responder imputation.Results In patients with an inadequate response to methotrexate, 60.2% and 54.6% receiving de novo filgotinib 200 mg and 100 mg had an ACR20 at week 156, respectively, as did 67.3% and 59.5% of those who continued filgotinib 200 mg and 100 mg. …”
Get full text
Article -
979
-
980